nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective
|
Fosså, S.D. |
|
|
34 |
12 |
p. 1165-1174 |
artikel |
2 |
Annals of Oncology 2018-2023
|
Andre, F. |
|
|
34 |
12 |
p. 1069-1070 |
artikel |
3 |
Changing cancer representations toward comprehensive portraits to empower patients in their care journey
|
Franzoi, M.A. |
|
|
34 |
12 |
p. 1082-1087 |
artikel |
4 |
Circulating tumour DNA for detection of minimal residual disease in head and neck squamous cell carcinoma: A new hope
|
Jacky Lam, W.K. |
|
|
34 |
12 |
p. 1080-1081 |
artikel |
5 |
Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company’s data collection, reporting, and interpretation of race and ethnicity
|
Candelario, N.M. |
|
|
34 |
12 |
p. 1194-1197 |
artikel |
6 |
Editorial Board
|
|
|
|
34 |
12 |
p. iii |
artikel |
7 |
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
|
Castelo-Branco, L. |
|
|
34 |
12 |
p. 1097-1112 |
artikel |
8 |
Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now?
|
D’Souza, A. |
|
|
34 |
12 |
p. 1077-1079 |
artikel |
9 |
High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer
|
Bessa, X. |
|
|
34 |
12 |
p. 1187-1193 |
artikel |
10 |
Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma
|
McNeish, I.A. |
|
|
34 |
12 |
p. 1074-1076 |
artikel |
11 |
Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
|
Goetz, M.P. |
|
|
34 |
12 |
p. 1141-1151 |
artikel |
12 |
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
|
Pujade-Lauraine, E. |
|
|
34 |
12 |
p. 1152-1164 |
artikel |
13 |
Moving toward precision oncology centers V2.0
|
Dogan, S. |
|
|
34 |
12 |
p. 1088-1089 |
artikel |
14 |
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
|
Damodaran, S. |
|
|
34 |
12 |
p. 1131-1140 |
artikel |
15 |
Retraction notice to “CN5 - Examination of mobile applications on breast cancer”
|
Aydin, A. |
|
|
34 |
12 |
p. 1201 |
artikel |
16 |
Retraction notice to “CN104 - How should the symptoms be managed after breast cancer surgery? An example of mobile app”
|
Aydin, A. |
|
|
34 |
12 |
p. 1203 |
artikel |
17 |
Retraction notice to “CN17 - Using mobile-based health care applications outcomes: Mini systematic review”
|
Aydin, A. |
|
|
34 |
12 |
p. 1202 |
artikel |
18 |
Table of Contents
|
|
|
|
34 |
12 |
p. i-ii |
artikel |
19 |
The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer
|
Wander, Seth A. |
|
|
34 |
12 |
p. 1071-1073 |
artikel |
20 |
The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review
|
Fulton-Ward, T. |
|
|
34 |
12 |
p. 1113-1130 |
artikel |
21 |
Time to treat the climate and nature crisis as one indivisible global health emergency ☆
|
Abbasi, K. |
|
|
34 |
12 |
p. 1094-1096 |
artikel |
22 |
Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck
|
Honoré, N. |
|
|
34 |
12 |
p. 1175-1186 |
artikel |
23 |
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
|
Oaknin, A. |
|
|
34 |
12 |
p. 1198-1200 |
artikel |
24 |
WGS/WES-RNAseq compared to targeted NGS in oncology: is there something to unlock?
|
Aldea, M. |
|
|
34 |
12 |
p. 1090-1093 |
artikel |